Home
|
About us
|
Editorial board
|
Search
|
Ahead of print
|
Current issue
|
Archives
|
Submit article
|
Instructions
|
Subscribe
|
Contacts
|
Advertise
|
Reader Login
Search Article
Advanced search
Users Online: 961
Export selected to
Endnote
Reference Manager
Procite
Medlars Format
RefWorks Format
BibTex Format
Citation statistics : Table of Contents
2013| November | Volume 17 | Issue 8
Online since
November 27, 2013
Archives
Previous Issue
Next Issue
Most popular articles
Most cited articles
Show all abstracts
Show selected abstracts
Export selected to
Cited
Viewed
PDF
ORIGINAL ARTICLES
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the South India cohort of the A
1
chieve study
S Nallaperumal, Johny Kannampilly
November 2013, 17(8):496-500
DOI
:10.4103/2230-8210.122095
PMID
:24404490
Background:
The A
1
chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (
n
= 66,726) in routine clinical care across four continents.
Materials and Methods:
Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from South India.
Results:
A total of 9273 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Patients had started on or were switched to biphasic insulin aspart (
n
= 7217), insulin detemir (
n
= 1001), insulin aspart (
n
= 734), basal insulin plus insulin aspart (
n
= 117) and other insulin combinations (
n
= 189). At baseline glycaemic control was poor for both insulin naïve (mean HbA
1
c: 9.2%) and insulin user (mean HbA
1
c: 9.1%) groups. After 24 weeks of treatment both the groups showed improvement in HbA
1
c (insulin naïve: −1.6%, insulin users: −1.3%). SADRs including major hypoglycaemic events or episodes did not occur in any of the study patients.
Conclusion:
Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
[PubMed]
7
808
211
EDITORIALS
Kleiber's law and the A
1
chieve study
Sanjay Kalra, Siddharth N Shah, Rakesh Sahay
November 2013, 17(8):397-398
DOI
:10.4103/2230-8210.122039
PMID
:24404466
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
[PubMed]
1
1,130
217
ORIGINAL ARTICLES
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Mumbai cohort of the A
1
chieve study
PG Talwalkar, Vishal Gupta, Rajiv Kovil
November 2013, 17(8):516-520
DOI
:10.4103/2230-8210.122107
PMID
:24404494
Background:
The A
1
chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (
n
= 66,726) in routine clinical care across four continents.
Materials and Methods:
Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from Mumbai, India.
Results:
A total of 2112 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Patients had started on or were switched to biphasic insulin aspart (
n
= 1561), insulin detemir (
n
= 313), insulin aspart (
n
= 144), basal insulin plus insulin aspart (
n
= 53) and other insulin combinations (
n
= 41). At baseline glycaemic control was poor for both insulin naïve (mean HbA
1
c: 8.7%) and insulin user (mean HbA
1
c: 9.2%) groups. After 24 weeks of treatment, both the groups showed improvement in HbA
1
c (insulin naïve: −1.4%, insulin users: −1.8%). SADRs including major hypoglycaemic events or episodes did not occur in any of the study patients.
Conclusion:
Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
[PubMed]
1
749
201
EDITORIALS
The A
1
chieve study: Mapping the Ibn Battuta trail
Sanjay Kalra, Mahdi Kamoun, Siddharth N Shah
November 2013, 17(8):395-396
DOI
:10.4103/2230-8210.122038
PMID
:24404465
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
-
1,101
289
ORIGINAL ARTICLES
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the East India cohort of the A
1
chieve study
Abhay Kumar Sahoo, Sambit Das, Pitambar Prusty, Anand Shankar, Shaibal Guha
November 2013, 17(8):501-505
DOI
:10.4103/2230-8210.122096
PMID
:24404491
Background:
The A1chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (
n
= 66,726) in routine clinical care across four continents.
Materials and Methods:
Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from East India.
Results:
A total of 2177 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Patients had started on or were switched to biphasic insulin aspart (
n
=1605), insulin detemir (
n
=230), insulin aspart (
n
=233), basal insulin plus insulin aspart (
n
=49) and other insulin combinations (
n
=54). At baseline glycaemic control was poor for both insulin naïve (mean HbA1c: 8.9%) and insulin user (mean HbA1c: 9.1%) groups. After 24 weeks of treatment, both the groups showed improvement in HbA1c (insulin naïve: -1.6%, insulin users: -1.6%). SADRs including major hypoglycaemic events or episodes did not occur in any of the study patients.
Conclusion:
Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
-
777
177
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the North East India cohort of the A
1
chieve study
Debmalya Sanyal, Debasis Basu, Mihir Saikia
November 2013, 17(8):506-510
DOI
:10.4103/2230-8210.122102
PMID
:24404492
Background:
The A
1
chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (
n
= 66,726) in routine clinical care across four continents.
Materials and Methods:
Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from North East, India.
Results:
A total of 730 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Patients had started on or were switched to biphasic insulin aspart (
n
= 518), insulin detemir (
n
= 88), insulin aspart (
n
= 74), basal insulin plus insulin aspart (
n
= 19) and other insulin combinations (
n
= 30). At baseline glycaemic control was poor for both insulin naïve (mean HbA
1
c: 9.5%) and insulin users (mean HbA
1
c: 9.2%) groups. After 24 weeks of treatment, both groups showed improvement in HbA
1
c (insulin naïve: −1.6%, insulin users: −1.5%). SADRs including major hypoglycaemic events or episodes did not occur in any of the study patients.
Conclusion:
Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
-
770
190
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Maharashtra cohort of the A
1
chieve study
Uday Phadke, Sunil Gupta, Vaishali Deshmukh
November 2013, 17(8):511-515
DOI
:10.4103/2230-8210.122104
PMID
:24404493
Background:
The A
1
chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (
n
= 66,726) in routine clinical care across four continents.
Materials and Methods:
Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from Maharashtra, India.
Results:
A total of 3069 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Patients had started on or were switched to biphasic insulin aspart (
n
= 2115), insulin detemir (
n
= 461), insulin aspart (
n
= 333), basal insulin plus insulin aspart (
n
= 92) and other insulin combinations (
n
= 61). At baseline glycaemic control was poor for both insulin naïve (mean HbA
1
c: 8.8) and insulin user (mean HbA
1
c: 9.1%) groups. After 24 weeks of treatment, both the groups showed improvement in HbA
1
c (insulin naïve: −1.4%, insulin users: −1.4%). SADRs including major hypoglycaemic events or episodes did not occur in any of the study patients.
Conclusion:
Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
-
676
170
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Gujarat cohort of the A
1
chieve study
Banshi Saboo, Mayur Patel
November 2013, 17(8):521-525
DOI
:10.4103/2230-8210.122113
PMID
:24404495
Background:
The A
1
chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (
n
= 66,726) in routine clinical care across four continents.
Materials and Methods:
Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from Gujarat, India.
Results:
A total of 812 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Patients had started on or were switched to biphasic insulin aspart (
n
= 502), insulin detemir (
n
= 89), insulin aspart (
n
= 155), basal insulin plus insulin aspart (
n
= 45) and other insulin combinations (
n
= 21). At baseline glycaemic control was poor for both insulin naïve (mean HbA
1
c: 8.9%) and insulin user (mean HbA
1
c: 9.1%) groups. After 24 weeks of treatment, both the groups showed improvement in HbA
1
c (insulin naïve: −2.2%, insulin users: −2.5%). SADRs including major hypoglycaemic events or episodes did not occur in any of the study patients.
Conclusion:
Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
-
657
170
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Rajasthan cohort of the A
1
chieve study
Akhil Joshi, Anand Meenawat, Rajeev Patni, DC Sharma, Shashi Panicker
November 2013, 17(8):526-529
DOI
:10.4103/2230-8210.122116
PMID
:24404496
Background:
The A
1
chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (
n
= 66,726) in routine clinical care across four continents.
Materials and Methods:
Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from Rajasthan, India.
Results:
A total of 477 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Patients had started on or were switched to biphasic insulin aspart (
n
= 340), insulin detemir (
n
= 90), insulin aspart (
n
= 37), basal insulin plus insulin aspart (
n
= 7) and other insulin combinations (
n
= 2). At baseline glycaemic control was poor for both insulin naïve (mean HbA
1
c: 8.3%) and insulin user (mean HbA
1
c: 8.4%) groups. After 24 weeks of treatment, both the groups showed improvement in HbA
1
c (insulin naïve: −0.9%, insulin users: −1.2%). Major hypoglycaemic events decreased from 0.5 events/patient-year to 0.0 events/patient-year in insulin naïve group while no change from baseline (1.3 events/patients-year) was observed for insulin users. SADRs were not reported in any of the study patients.
Conclusion:
Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
-
778
186
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Delhi cohort of the A
1
chieve study
Sudhir Tripathi, Neeru Gera, Anil Motta, Rajiva Gupta
November 2013, 17(8):530-533
DOI
:10.4103/2230-8210.122118
PMID
:24404497
Background:
The A
1
chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (
n
= 66,726) in routine clinical care across four continents.
Materials and Methods:
Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from Delhi, India.
Results:
A total of 2242 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Patients had started on or were switched to biphasic insulin aspart (
n
= 1515), insulin detemir (
n
= 521), insulin aspart (
n
= 176), basal insulin plus insulin aspart (
n
= 11) and other insulin combinations (
n
= 19). At baseline glycaemic control was poor for both insulin naïve (mean HbA
1
c: 10.0%) and insulin user (mean HbA
1
c: 11.0%) groups. After 24 weeks of treatment both the groups showed improvement in HbA
1
c (insulin naïve: −3.1%, insulin users: −3.6%). SADRs including major hypoglycaemic events or episodes did not occur in any of the study patients.
Conclusion:
Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
-
677
178
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Punjab cohort of the A
1
chieve study
Parminder Singh, KP Singh, Gagan Priya, Rohit Kapoor
November 2013, 17(8):534-537
DOI
:10.4103/2230-8210.122120
PMID
:24404498
Background:
The A
1
chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (
n
= 66,726) in routine clinical care across four continents.
Materials and Methods:
Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from Punjab, India.
Results:
A total of 655 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Patients had started on or were switched to biphasic insulin aspart (
n
= 587), insulin detemir (
n
= 28), insulin aspart (
n
= 24), basal insulin plus insulin aspart (
n
= 13) and other insulin combinations (
n
= 3). At baseline glycaemic control was poor for both insulin naïve (mean HbA
1
c: 9.1%) and insulin user (mean HbA
1
c: 9.1%) groups. After 24 weeks of treatment, both the groups showed improvement in HbA
1
c (insulin naïve: −0.8%, insulin users: −1.0%). SADRs including major hypoglycaemic events or episodes did not occur in any of the study patients.
Conclusion:
Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
-
689
172
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Haryana cohort of the A
1
chieve study
Sanjay Kalra, Lokesh Garg, Sandeep Suri, Sameer Aggarwal
November 2013, 17(8):538-541
DOI
:10.4103/2230-8210.122122
PMID
:24404499
Background:
The A
1
chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (
n
= 66,726) in routine clinical care across four continents.
Materials and Methods:
Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from Haryana, India.
Results:
A total of 345 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Patients had started on or were switched to biphasic insulin aspart (
n
= 236), insulin detemir (
n
= 66), insulin aspart (
n
= 28), basal insulin plus insulin aspart (
n
= 1) and other insulin combinations (
n
= 14). At baseline glycaemic control was poor for both insulin naïve (mean HbA
1
c: 10.7%) and insulin user (mean HbA
1
c: 10.5%) groups. After 24 weeks of treatment, both the groups showed improvement in HbA
1
c (insulin naïve: −3.9%, insulin users: −3.3%). SADRs including major hypoglycaemic events or episodes did not occur in any of the study patients.
Conclusion:
Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
-
676
168
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Andhra Pradesh cohort of the A
1
chieve study
Mohammed Abubaker, Y Sadasiva Rao, Samir Hamid Zargar, Raman Shetty, Ravi Shankar
November 2013, 17(8):542-546
DOI
:10.4103/2230-8210.122129
PMID
:24404500
Background:
The A
1
chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (
n
= 66,726) in routine clinical care across four continents.
Materials and Methods:
Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from Andhra Pradesh, India.
Results:
A total of 3077 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Patients had started on or were switched to biphasic insulin aspart (
n
= 2452), insulin detemir (
n
= 308), insulin aspart (
n
= 226), basal insulin plus insulin aspart (
n
= 21) and other insulin combinations (
n
= 68). At baseline glycaemic control was poor for both insulin naïve (mean HbA
1
c: 8.9%) and insulin user (mean HbA
1
c: 9.2%) groups. After 24 weeks of treatment, both the groups showed improvement in HbA
1
c (insulin naïve: −1.2%, insulin users: −1.1%). SADRs including major hypoglycaemic events or episodes did not occur in any of the study patients.
Conclusion:
Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
-
693
195
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Hyderabad cohort of the A
1
chieve study
R Santosh, Ravi Mehrotra, NG Sastry
November 2013, 17(8):547-551
PMID
:24404501
Background:
The A
1
chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (
n
= 66,726) in routine clinical care across four continents.
Materials and Methods:
Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from Hyderabad, India.
Results:
A total of 1249 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Patients had started on or were switched to biphasic insulin aspart (
n
= 893), insulin detemir (
n
= 158), insulin aspart (
n
= 124), basal insulin plus insulin aspart (
n
= 19) and other insulin combinations (
n
= 54). At baseline glycaemic control was poor for both insulin naïve (mean HbA1c: 9.0%) and insulin user (mean HbA1c: 9.5%) groups. After 24 weeks of treatment, both the groups showed improvement in HbA1c (insulin naïve: −0.9%, insulin users: −1.1%). SADRs including major hypoglycaemic events or episodes did not occur in any of the study patients.
Conclusion:
Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
-
938
172
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Karnataka cohort of the A
1
chieve study
Neeta Deshpande, Vageesh Ayyar, Rajkumar Channabasavaiah, Raman Shetty, Anish Behl
November 2013, 17(8):552-556
DOI
:10.4103/2230-8210.122132
PMID
:24404502
Background:
The A
1
chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (
n
= 66,726) in routine clinical care across four continents.
Materials and Methods:
Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from Karnataka, India.
Results:
A total of 2243 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Patients had started on or were switched to biphasic insulin aspart (
n
= 1855), insulin detemir (
n
= 211), insulin aspart (
n
= 111), basal insulin plus insulin aspart (
n
= 16) and other insulin combinations (
n
= 40). At baseline glycaemic control was poor for both insulin naïve (mean HbA
1
c: 9.2%) and insulin user (mean HbA
1
c: 9.0%) groups. After 24 weeks of treatment, both the groups showed improvement in HbA
1
c (insulin naïve: −1.4%, insulin users: −1.7%). SADRs including major hypoglycaemic events or episodes did not occur in any of the study patients.
Conclusion:
Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
-
722
197
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Bangalore cohort of the A
1
chieve study
L Srinivasa Murthy, S Paramesh
November 2013, 17(8):557-560
DOI
:10.4103/2230-8210.122135
PMID
:24404503
Background:
The A
1
chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (
n
= 66,726) in routine clinical care across four continents.
Materials and Methods:
Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from Bangalore, India.
Results:
A total of 1533 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Patients had started on or were switched to biphasic insulin aspart (
n
= 1262), insulin detemir (
n
= 165), insulin aspart (
n
= 86), basal insulin plus insulin aspart (
n
= 11) and other insulin combinations (
n
= 2). At baseline glycaemic control was poor for both insulin naïve (mean HbA
1
c: 9.2%) and insulin users (mean HbA
1
c: 8.8%) groups. After 24 weeks of treatment, both groups showed improvement in HbA
1
c (insulin naïve: −1.3%, insulin users: −1.5%). SADRs including major hypoglycaemic events or episodes did not occur in any of the study patients.
Conclusion:
Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
-
611
170
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Kerala cohort of the A
1
chieve study
Sreejith N Kumar, Tom Babu, VM Haridas
November 2013, 17(8):561-564
DOI
:10.4103/2230-8210.122136
PMID
:24404504
Background:
The A
1
chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (
n
= 66,726) in routine clinical care across four continents.
Materials and Methods:
Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from Kerala, India.
Results:
A total of 1732 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Patients had started on or were switched to biphasic insulin aspart (
n
= 1203), insulin detemir (
n
= 212), insulin aspart (
n
= 312), basal insulin plus insulin aspart (
n
= 1) and other insulin combinations (
n
= 1). At baseline glycaemic control was poor for both insulin naïve (mean HbA
1
c: 10.0%) and insulin user (mean HbA
1
c: 8.3%) groups. After 24 weeks of treatment, both the groups showed improvement in HbA
1
c (insulin naïve: −2.4%, insulin users: −0.5%). SADRs including major hypoglycaemic events or episodes did not occur in any of the study patients.
Conclusion:
Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
-
670
179
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Trivandrum cohort of the A
1
chieve study
Jothydev Kesavadev
November 2013, 17(8):565-568
DOI
:10.4103/2230-8210.122138
PMID
:24404505
Background:
The A1chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (
n
= 66,726) in routine clinical care across four continents.
Materials and
Methods:
Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from Trivandrum, India.
Results:
A total of 528 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Patients had started on or were switched to biphasic insulin aspart (
n
= 392), insulin detemir (
n
= 65), insulin aspart (
n
= 70) and other insulin combinations (
n
= 1). At baseline glycaemic control was poor for both insulin naïve (mean HbA
1
c: 9.9%) and insulin user (mean HbA
1
c: 8.1%) groups. After 24 weeks of treatment, both the study groups showed improvement in HbA
1
c (insulin naïve: −2.4%, insulin users: −1.0%). SADRs including major hypoglycaemic events or episodes did not occur in any of the study patients.
Conclusion:
Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
-
738
180
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Tamil Nadu cohort of the A
1
chieve study
M Shunmugavelu, J Giri, Shahid Akhtar, Raman Shetty, AJ Asirvatham
November 2013, 17(8):569-573
DOI
:10.4103/2230-8210.122139
PMID
:24404506
Background:
The A
1
chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (
n
= 66,726) in routine clinical care across four continents.
Materials and Methods:
Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from Tamil Nadu, India.
Results:
A total of 2221 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Patients had started on or were switched to biphasic insulin aspart (
n
= 1707), insulin detemir (
n
= 270), insulin aspart (
n
= 85), basal insulin plus insulin aspart (
n
= 79) and other insulin combinations (
n
= 80). At baseline glycaemic control was poor for both insulin naïve (mean HbA
1
c: 9.2%) and insulin user (mean HbA
1
c: 9.2%) groups. After 24 weeks of treatment, both the groups showed improvement in HbA
1
c (insulin naïve: −1.7%, insulin users: −1.7%). SADRs including major hypoglycaemic events did not occur in any of the study patients.
Conclusion:
Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
-
717
182
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Chennai cohort of the A
1
chieve study
JS Kumar, A Paneerselvam
November 2013, 17(8):574-578
DOI
:10.4103/2230-8210.122141
PMID
:24404507
Background:
The A
1
chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (
n
= 66,726) in routine clinical care across four continents.
Materials and Methods:
Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from Chennai, India.
Results:
A total of 1334 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Patients had started on or were switched to biphasic insulin aspart (
n
= 983), insulin detemir (
n
= 205), insulin aspart (
n
= 42), basal insulin plus insulin aspart (
n
= 41) and other insulin combinations (
n
= 63). At baseline glycaemic control was poor for both insulin naïve (mean HbA
1
c: 9.4%) and insulin users (mean HbA
1
c: 9.3%) groups. After 24 weeks of treatment, both groups showed improvement in HbA
1
c (insulin naïve: −2.1%, insulin users: −1.9%). SADRs including major hypoglycaemic events or episodes did not occur in any of the study patients.
Conclusion:
Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
-
611
179
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the West Bengal cohort of the A
1
chieve study
Satinath Mukhopadhyay, Nilanjan Sengupta, Sujoy Ghosh
November 2013, 17(8):579-583
DOI
:10.4103/2230-8210.122142
PMID
:24404508
Background:
The A
1
chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (
n
= 66,726) in routine clinical care across four continents.
Materials and Methods:
Data was collected at baseline, 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from West Bengal, India.
Results:
A total of 1133 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Patients had started on or were switched to biphasic insulin aspart (
n
= 897), insulin detemir (
n
= 94), insulin aspart (
n
= 90), basal insulin plus insulin aspart (
n
= 28) and other insulin combinations (
n
= 19). At baseline glycaemic control was poor for both insulin naïve (mean HbA
1
c: 8.5%) and insulin user (mean HbA
1
c: 8.9%) groups. After 24 weeks of treatment, both the study groups showed improvement in HbA
1
c (insulin naïve: −1.3%, insulin users: −1.6%). SADRs including major hypoglycaemic events or episodes did not occur in any of the study patients.
Conclusion:
Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
-
753
206
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Kolkata cohort of the A
1
chieve study
Anirban Majumder, Awadhesh Kumar Singh, Kalyan Kumar Gangopadhyay, Ranjini Sen, Raman Shetty, Sujoy Majumdar
November 2013, 17(8):584-587
DOI
:10.4103/2230-8210.122144
PMID
:24404509
Background:
The A
1
chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (
n
= 66,726) in routine clinical care across four continents.
Materials and Methods:
Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from Kolkata, India.
Results:
A total of 576 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Patients had started on or were switched to biphasic insulin aspart (
n
= 417), insulin detemir (
n
= 70), insulin aspart (
n
= 55), basal insulin plus insulin aspart (
n
= 19) and other insulin combinations (
n
= 15). At baseline, glycaemic control was poor for both insulin naïve (mean HbA
1
c: 8.3%) and insulin user (mean HbA
1
c: 8.6%) groups. After 24 weeks of treatment, both the groups showed improvement in HbA
1
c (insulin naïve: −1.3%, insulin users: −1.4%). SADRs including major hypoglycaemic events or episodes did not occur in any of the study patients.
Conclusion:
Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
-
761
197
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Agadir cohort of the A
1
chieve study
Hicham Boussouf, Mahassine Mouniri, Maha Oudrhiri
November 2013, 17(8):399-403
DOI
:10.4103/2230-8210.122040
PMID
:24404467
Background:
A
1
chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (
n
= 66,726) in routine clinical care across four continents.
Materials and Methods:
Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from Agadir, Morocco.
Results:
A total of 201 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Study patients had started on or were switched to biphasic insulin aspart (
n
= 98), insulin detemir (
n
= 54), insulin aspart (
n
= 8), basal insulin plus insulin aspart (
n
= 8) and other insulin combinations (
n
= 33). At baseline glycaemic control was poor for both insulin naïve (mean HbA
1
c: 10.7%) and insulin user (mean HbA
1
c: 9.1%) groups. After 24 weeks of treatment, both groups showed improvement in HbA
1
c (insulin naïve: −2.7%, insulin users: −1.3%). No major hypoglycaemia was observed at 24 weeks. SADRs were reported in 1.5% of insulin users.
Conclusion:
Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
-
804
222
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Marrakech cohort of the A
1
chieve study
El Ansari Nawal
November 2013, 17(8):404-407
DOI
:10.4103/2230-8210.122041
PMID
:24404468
Background:
The A
1
chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (
n
= 66,726) in routine clinical care across four continents.
Materials and Methods:
Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from Marrakech, Morocco.
Results:
A total of 196 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Study patients had started on or were switched to biphasic insulin aspart (
n
= 71), insulin detemir (
n
= 83), insulin aspart (
n
= 5), basal insulin plus insulin aspart (
n
= 14) and other insulin combinations (
n
= 23). At baseline glycaemic control was poor for both insulin naïve (mean HbA
1
c: 9.3%) and insulin user (mean HbA
1
c: 9.3%) groups. After 24 weeks of treatment, both the study groups showed improvement in HbA
1
c (insulin naïve: −2.3%, insulin users: −1.9%). SADR's including major hypoglycaemic events did not occur in any of the study patients.
Conclusion:
Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
-
816
200
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Casablanca cohort of the A
1
chieve study
Ahmed Farouqi, Asmae Chadli
November 2013, 17(8):408-412
DOI
:10.4103/2230-8210.122042
PMID
:24404469
Background:
The A
1
chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (
n
= 66,726) in routine clinical care across four continents.
Materials and Methods:
Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from Casablanca, Morocco.
Results:
A total of 495 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Study patients had started on or were switched to biphasic insulin aspart (
n
= 231), insulin detemir (
n
= 151), insulin aspart (
n
= 19), basal insulin plus insulin aspart (
n
= 53) and other insulin combinations (
n
= 41). At baseline glycaemic control was poor for both insulin naïve (mean HbA
1
c: 10.2%) and insulin user (mean HbA
1
c: 9.4%) groups. After 24 weeks of treatment, both groups showed improvement in HbA
1
c (insulin naïve: −2.3%, insulin users: −1.8%). Major hypoglycaemia was observed in the insulin naïve group after 24 weeks. SADRs were reported in 1.2% of insulin naïve and 2.1% of insulin user groups.
Conclusion:
Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
-
798
276
Clinical experience with insulin detemir type 2 diabetes mellitus, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Rabat-Sale-Zemmour-Zaer Region cohort of the A
1
chieve study
Abdelmjid Chraibi, Ghizlane Belmejdoub
November 2013, 17(8):413-417
DOI
:10.4103/2230-8210.122045
PMID
:24404470
Background:
The A
1
chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (
n
= 66 726) in routine clinical care across four continents.
Materials and Methods:
Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from Rabat-Sale-Zemmour-Zaer region, Morocco.
Results:
A total of 424 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Study patients had started on or were switched to biphasic insulin aspart (
n
= 177), insulin detemir (
n
= 150), insulin aspart (
n
= 11), basal insulin plus insulin aspart (
n
= 45) and other insulin combinations (
n
= 41). At baseline glycaemic control was poor for both insulin naïve (mean HbA
1
c: 10.1%) and insulin user (mean HbA
1
c: 9.4%) groups. After 24 weeks of treatment, all the study groups showed improvement in HbA
1
c (insulin naïve: −2.5%, insulin users: −1.8%). Major hypoglycaemia was observed in the insulin user group after 24 weeks (0.1 events/patient-year). SADRs were reported in 0.5% of insulin users.
Conclusion:
Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
-
768
197
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from North and the oriental region of Morocco cohort of the A
1
chieve study
Othmane Laaribi
November 2013, 17(8):418-421
DOI
:10.4103/2230-8210.122047
PMID
:24404471
Background:
The A
1
chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (
n
= 66 726) in routine clinical care across four continents.
Materials and Methods:
Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from Oriental, Morocco.
Results:
A total of 180 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Study patients had started on or were switched to biphasic insulin aspart (
n
= 146), insulin detemir (
n
= 22), insulin aspart (
n
= 6), basal insulin plus insulin aspart (
n
= 2) and other insulin combinations (
n
= 4). At baseline glycaemic control was poor for both insulin naïve (mean HbA
1
c: 9.0%) and insulin user (mean HbA
1
c: 8.8%) groups. After 24 weeks of treatment, both the study groups showed improvement in HbA
1
c (insulin naïve: −1.7%, insulin users: −1.6%). SADRs including major hypoglycaemia did not occur in any of the study patients.
Conclusion:
Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
-
680
186
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Saiss cohort of the A
1
chieve study
Farida Ajdi
November 2013, 17(8):422-425
DOI
:10.4103/2230-8210.122051
PMID
:24404472
Background:
The A
1
chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (
n
= 66 726) in routine clinical care across four continents.
Materials and Methods:
Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from Saiss, Morocco.
Results:
A total of 145 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Study patients had started on or were switched to biphasic insulin aspart (
n
= 47), insulin detemir (
n
= 56), insulin aspart (
n
= 1), basal insulin plus insulin aspart (
n
= 35) and other insulin combinations (
n
= 6). At baseline glycaemic control was poor for both insulin naïve (mean HbA1c: 10.4%) and insulin user (mean HbA1c: 9.8%) groups. After 24 weeks of treatment, both the study groups showed improvement in HbA1c (insulin naïve: −2.7%, insulin users: −2.5%). SADRs including major hypoglycaemia did not occur in any of the study patients.
Conclusion:
Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
-
1,034
189
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Northern Tunisia cohort of the A
1
chieve study
Samira Blouza, Henda Jamoussi
November 2013, 17(8):426-430
DOI
:10.4103/2230-8210.122057
PMID
:24404473
Background:
The A
1
chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (
n
= 66,726) in routine clinical care across four continents.
Materials and Methods:
Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from Northern Tunisia.
Results:
A total of 443 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Study patients had started on or were switched to biphasic insulin aspart (
n
= 137), insulin detemir (
n
= 243), insulin aspart (
n
= 11), basal insulin plus insulin aspart (
n
= 39) and other insulin combinations (
n
= 13). At baseline glycaemic control was poor for both insulin naïve (mean HbA
1
c: 10.2%) and insulin user (mean HbA
1
c: 9.8%) groups. After 24 weeks of treatment, both the study groups showed improvement in HbA
1
c (insulin naïve: −2.1%, insulin users: −0.9%). SADRs including major hypoglycaemic events or episodes did not occur in any of the study patients.
Conclusion:
Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
-
675
203
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Central and Southern Tunisia cohort of the A
1
chieve study
Mohamed Abid, Ines Khochtali
November 2013, 17(8):431-434
DOI
:10.4103/2230-8210.122059
PMID
:24404474
Background:
The A
1
chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (
n
= 66,726) in routine clinical care across four continents.
Materials and Methods:
Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from Central and Southern Tunisia.
Results:
A total of 142 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Study patients had started on or were switched to biphasic insulin aspart (
n
= 32), insulin detemir (
n
= 66), insulin aspart (
n
= 2), basal insulin plus insulin aspart (
n
= 39) and other insulin combinations (
n
= 3). At baseline glycaemic control was poor for both insulin naïve (mean HbA
1
c: 10.5%) and insulin user (mean HbA
1
c: 9.9%) groups. After 24 weeks of treatment, both groups showed improvement in HbA
1
c (insulin naïve: −2.4%, insulin users: −1.7%). SADRs including major hypoglycaemic events or episodes did not occur in any of the study patients.
Conclusion:
Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
-
823
213
Clinical experience with biphasic insulin aspart in people with type 2 diabetes: Results from the Libya cohort of the A
1
chieve study
Issam M Hajjaji, Ibrahim Sherif, Aisha Elazrag, Suhair Jaber, Praful N Chakkarwar, Salem Eltabal
November 2013, 17(8):435-436
DOI
:10.4103/2230-8210.122062
PMID
:24404475
Background:
The A
1
chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (
n
= 66,726) in routine clinical care across four continents.
Materials and Methods:
Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled in biphasic insulin aspart sub group from Libya.
Results:
A total of 179 patients were enrolled in the biphasic insulin aspart subgroup. All the patients were prior insulin users. At baseline glycaemic control was poor (mean HbA
1
c: 9.3%). After 24 weeks of treatment there was an improvement in HbA
1
c (−0.9%). Hypoglycaemic events reduced from 7.2 events/patient-year to 3.7 events/patient-year in 24 weeks. SADRs did not occur in any of the study patients.
Conclusion:
Starting or switching to biphasic insulin aspart was associated with improvement in glycaemic control with a low rate of hypoglycaemia.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
-
751
186
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Taif, Saudi Arabia cohort of the A
1
chieve study
Helmy El Gendy, Saud Al Sifri, Mohamed Ghazy
November 2013, 17(8):437-440
DOI
:10.4103/2230-8210.122063
PMID
:24404476
Background:
The A
1
chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (
n
= 66,726) in routine clinical care across four continents.
Materials and Methods:
Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for participants enrolled from Taif, Saudi Arabia.
Results:
A total of 791 subjects were enrolled in the study. Four different insulin analogue regimens were used in the study. Study patients were started on or were switched to biphasic insulin aspart (
n
= 238), insulin detemir (
n
= 325), insulin aspart (
n
= 9), basal insulin plus insulin aspart (
n
= 85) and other insulin combinations (
n
= 127). At baseline glycaemic control was poor for both insulin naïve (mean HbA
1
c: 9.7%) and insulin user (mean HbA
1
c: 9.8%) groups. After 24 weeks of treatment, both the study groups showed improvement in HbA
1
c (insulin naïve: −2.3%, insulin users: −2.6%). SADRs including major hypoglycaemic events did not occur in the study patients.
Conclusion:
Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
-
764
205
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Yanbu cohort of the A
1
chieve study
Moody El Harby, Ahmed Saeed
November 2013, 17(8):441-444
DOI
:10.4103/2230-8210.122065
PMID
:24404477
Background:
The A
1
chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (
n
= 66,726) in routine clinical care across four continents.
Materials and Methods:
Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from Yanbu, Saudi Arabia.
Results:
A total of 499 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Study patients had started on or were switched to biphasic insulin aspart (
n
= 256), insulin detemir (
n
= 146), insulin aspart (
n
= 3), basal insulin plus insulin aspart (
n
= 55) and other insulin combinations (
n
= 37). At baseline glycaemic control was poor for both insulin naïve (mean HbA
1
c: 9.4%) and insulin user (mean HbA
1
c: 9.5%) groups. After 24 weeks of treatment, both the study groups showed improvement in HbA
1
c (insulin naïve: −2.1%, insulin users: −1.8%). SADRs including major hypoglycaemic events did not occur in the study patients.
Conclusion:
Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
-
674
168
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Central Saudi Arabia cohort of the A
1
chieve study
Muhamed Shahed Omar, Najim Abdulwahid, Syed Salman Ali
November 2013, 17(8):445-448
DOI
:10.4103/2230-8210.122067
PMID
:24404478
Background:
The A
1
chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (
n
= 66,726) in routine clinical care across four continents.
Materials and Methods:
Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from Central Saudi Arabia.
Results:
A total of 2819 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Study patients had started on or were switched to biphasic insulin aspart (
n
= 1100), insulin detemir (
n
= 1156), insulin aspart (
n
= 34), basal insulin plus insulin aspart (
n
= 314) and other insulin combinations (
n
= 170). At baseline glycaemic control was poor for both insulin naïve (mean HbA
1
c: 9.9%) and insulin user (mean HbA
1
c: 9.8%) groups. After 24 weeks of treatment, both the groups showed improvement in HbA
1
c (insulin naïve: −2.6%, insulin users: −2.5%). SADRs including major hypoglycaemic events did not occur in the study patients.
Conclusion:
Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
-
819
192
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Southwest Saudi Arabia cohort of the A
1
chieve study
Waffaa Shawkat, Magdy Abdou, Nadia Ghannam, Ashraf Shaaban Mahfouz
November 2013, 17(8):449-452
DOI
:10.4103/2230-8210.122070
PMID
:24404479
Background:
The A
1
chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (
n
= 66,726) in routine clinical care across four continents.
Materials and Methods:
Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from southwest Saudi Arabia.
Results:
A total of 2561 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Study patients had started on or were switched to biphasic insulin aspart (
n
= 987), insulin detemir (
n
= 1121), insulin aspart (
n
= 21), basal insulin plus insulin aspart (
n
= 280) and missing or other insulin combinations (
n
= 152). At baseline glycaemic control was poor for both insulin naïve (mean HbA
1
c: 9.9%) and insulin user (mean HbA
1
c: 9.5%) groups. After 24 weeks of treatment, both the study groups showed improvement in HbA
1
c (insulin naïve: −2.5%, insulin users: −2.2%). Major hypoglycaemic events did not occur in any of the study patients. SADRs were reported in 0.1% of insulin naïve and 0.1% of insulin user groups.
Conclusion:
Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
-
702
176
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Eastern Saudi Arabia cohort of the A
1
chieve study
Faisal Hashim, Muneeb Ahmed Yasser, Oussama Khatib
November 2013, 17(8):453-457
DOI
:10.4103/2230-8210.122074
PMID
:24404480
Background:
The A
1
chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (
n
= 66,726) in routine clinical care across four continents.
Materials and Methods:
Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from Eastern Saudi Arabia.
Results:
A total of 1040 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Study patients had started on or were switched to biphasic insulin aspart (
n
= 489), insulin detemir (
n
= 360), insulin aspart (
n
= 37), basal insulin plus insulin aspart (
n
= 96) and other insulin combinations (
n
= 57). At baseline glycaemic control was poor for both insulin naïve (mean HbA
1
c: 10.0%) and insulin user (mean HbA
1
c: 9.2%) groups. After 24 weeks of treatment, both the groups showed improvement in HbA
1
c (insulin naïve: −2.7%, insulin users: −1.7%). No major hypoglycaemic episodes were observed at 24 weeks. SADR was reported in 0.6% of insulin users.
Conclusion:
Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
-
704
206
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Yemen cohort of the A
1
chieve study
Zayed Atef, Abdulkareem Al-Khawlany, Abdalla A Gunaid
November 2013, 17(8):458-460
DOI
:10.4103/2230-8210.122076
PMID
:24404481
Background:
The A
1
chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (
n
= 66,726) in routine clinical care across four continents.
Materials and Methods:
Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from Yemen.
Results:
A total of 104 patients were enrolled in the study. Three different insulin analogue regimens were used in the study. Study patients had started on or were switched to biphasic insulin aspart (
n
= 94), insulin aspart (
n
= 4), basal insulin plus insulin aspart (
n
= 1) and other insulin combinations (
n
= 2). At baseline glycaemic control was poor for both insulin naïve (mean HbA1c: 10.6%) and insulin user (mean HbA1c: 9.8%) groups. After 24 weeks of treatment, both the study groups showed improvement in HbA1c (insulin naïve: −2.7%, insulin users: −1.8%). SADR's including major hypoglycaemia events did not occur in any of the study patients.
Conclusion:
Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
-
709
187
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Bahraini cohort of the A
1
chieve study
Wiam Ibrahim Hussein, Noha Taha
November 2013, 17(8):461-464
DOI
:10.4103/2230-8210.122078
PMID
:24404482
Background:
The A
1
chieve, is a multicentric (28 countries), 24-weeks, non-interventional study to evaluate the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (
n
= 66,726) in routine clinical care across four continents.
Materials and Methods:
Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from Manama, kingdom of Bahrain.
Results:
A total of 115 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Study patients had started on or were switched to biphasic insulin aspart (
n
= 67), insulin detemir (
n
= 16), insulin aspart (
n
= 4), basal insulin plus insulin aspart (
n
= 21) and other insulin combinations (
n
= 7). At baseline, glycaemic control was poor for both insulin naïve (mean HbA1c: 10.2%) and insulin users (mean HbA1c: 9.8%) groups. After 24 weeks of treatment, both the groups showed improvement in HbA1c (insulin naïve: −1.1%, insulin users: −1.3%). SADRs including major hypoglycaemic events did not occur in the study patients.
Conclusion:
Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
-
687
237
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Kuwait cohort of the A
1
chieve study
Alaa Daban, Hussain Haji Ali
November 2013, 17(8):465-468
DOI
:10.4103/2230-8210.122080
PMID
:24404483
Background:
The A
1
chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (
n
= 66,726) in routine clinical care across four continents.
Materials and Methods:
Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from Kuwait.
Results:
A total of 1185 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Study patients had started on or were switched to biphasic insulin aspart (
n
= 472), insulin detemir (
n
= 472), insulin aspart (
n
= 4), basal insulin plus insulin aspart (
n
= 188) and other insulin combinations (
n
= 48). At baseline, glycaemic control was poor for both insulin naïve (mean HbA
1
c: 9.8%) and insulin user (mean HbA
1
c: 9.4%) groups. After 24 weeks of treatment, both the groups showed improvement in HbA
1
c (insulin naïve: −2.4%, insulin users: −1.7%). No major hypoglycaemic episodes were observed at 24 weeks. SADR was reported in 0.1% of insulin users.
Conclusion:
Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
-
658
169
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Qatar cohort of the A
1
chieve study
Mohamed Hasan Daghash, Jabbar Mubarak Raja, Mohamed Milad
November 2013, 17(8):469-471
DOI
:10.4103/2230-8210.122081
PMID
:24404484
Background:
The A
1
chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (
n
= 66,726) in routine clinical care across four continents.
Materials and Methods:
Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from Qatar.
Results:
A total of 91 patients were enrolled in the study. Two insulin analogue regimens were used in the study. Study patients had started on or were switched to biphasic insulin aspart (
n
= 88), insulin detemir (
n
= 2), and other insulin combinations (
n
= 1). At baseline glycaemic control was poor for both insulin naïve (mean HbA
1
c: 10.9%) and insulin users (mean HbA
1
c: 9.1%) groups. After 24 weeks of treatment, all the study groups showed improvement in HbA
1
c (insulin naïve: −1.8%, insulin users: −1.3%). Major hypoglycaemia did not occur in the study patients. SADRs were reported in 1.4% of insulin users.
Conclusion:
Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
-
659
180
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Dubai cohort of the A
1
chieve study
Zain Gulzar, Laxami Sharma, Thomas Zachariya
November 2013, 17(8):472-476
DOI
:10.4103/2230-8210.122084
PMID
:24404485
Background:
The A
1
chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (
n
= 66,726) in routine clinical care across four continents.
Materials and Methods:
Data was collected at baseline, at 12 weeks and at 24 weeks.This short communication presents the results for patients enrolled from Dubai.
Results:
A total of 767 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Study patients had started on or were switched to biphasic insulin aspart (
n
= 231), insulin detemir (
n
= 369), insulin aspart (
n
= 29), basal insulin plus insulin aspart (
n
= 111) and other insulin combinations (
n
= 26). At baseline glycaemic control was poor for both insulin naïve (mean HbA
1
c: 9.2%) and insulin user (mean HbA
1
c: 9.1%) groups. After 24 weeks of treatment, both the groups showed improvement in HbA
1
c (insulin naïve: −1.9%, insulin users: −1.8%). SADRs did not occur in any of the study patients. Major hypoglycaemia was nil similar to that of baseline in insulin naïve group whereas major hypoglycaemic events reduced from 0.3 events/patient-year to 0.1 events/patient-year in insulin users.
Conclusion:
Starting or switching to insulin analogues was associated with improvements in glycaemic control with a low rate of hypoglycaemia.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
-
680
201
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Abu Dhabi cohort of the A
1
chieve study
Oula Alhabian, Mowafaq Yehyia
November 2013, 17(8):477-481
DOI
:10.4103/2230-8210.122085
PMID
:24404486
Background:
The A
1
chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (
n
= 66,726) in routine clinical care across four continents.
Materials and Methods:
Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from Abu Dhabi.
Results:
A total of 383 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Study patients had started on or were switched to biphasic insulin aspart (
n
= 134), insulin detemir (
n
= 152), insulin aspart (
n
= 13), basal insulin plus insulin aspart (
n
= 42) and other insulin combinations (
n
= 41). At baseline glycaemic control was poor for both insulin naïve (mean HbA
1
c: 9.4%) and insulin user (mean HbA
1
c: 9.1%) groups. After 24 weeks of treatment, both groups showed improvement in HbA
1
c (insulin naïve: −2.1%, insulin users: −1.8%). SADRs did not occur in any of the study patients. Major hypoglycaemic events remained same as that of baseline (0.1 events/patient-year) for insulin naïve group whereas major hypoglycaemia reduced from 0.1 events/patient-year to 0.0 events/patient-year in insulin users.
Conclusion:
Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
-
619
192
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Oman cohort of the A
1
chieve study
Mustafa Al Abousi
November 2013, 17(8):482-485
DOI
:10.4103/2230-8210.122090
PMID
:24404487
Background:
The A
1
chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (
n
= 66,726) in routine clinical care across four continents.
Materials and Methods:
Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from Oman.
Results:
A total of 349 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Study patients had started on or were switched to biphasic insulin aspart (
n
= 121), insulin detemir (
n
= 171), insulin aspart (
n
= 2), basal insulin plus insulin aspart (
n
= 38) and other insulin combinations (
n
= 17). At baseline glycaemic control was poor for both insulin naïve (mean HbA
1
c: 9.2%) and insulin user (mean HbA
1
c: 8.8%) groups. After 24 weeks of treatment, both the groups showed improvement in HbA
1
c (insulin naïve: −2.1%, insulin users: −1.6%). SADRs including major hypoglycaemic events did not occur in the study patients.
Conclusion:
Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia and no weight gain.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
-
698
174
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the West India cohort of the A
1
chieve study
Sunil M Jain, Sushil Jindal, Harshad Malve, Raman Shetty, Anil Bhoraskar
November 2013, 17(8):486-490
DOI
:10.4103/2230-8210.122091
PMID
:24404488
Background:
The A
1
chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (
n
= 66,726) in routine clinical care across four continents.
Materials and
Methods:
Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from West India.
Results:
A total of 4192 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Patients had started on or were switched to biphasic insulin aspart (
n
= 2846), insulin detemir (
n
= 596), insulin aspart (
n
= 517), basal insulin plus insulin aspart (
n
= 140) and other insulin combinations (
n
= 83). At baseline glycaemic control was poor for both insulin naïve (mean HbA
1
c: 8.8%) and insulin user (mean HbA
1
c: 9.1%) groups. After 24 weeks of treatment, both the groups showed improvement in HbA
1
c (insulin naïve: −1.6%, insulin users: −1.7%). SADRs including major hypoglycaemic events or episodes did not occur in any of the study patients.
Conclusion:
Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
-
734
191
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the North India cohort of the A
1
chieve study
Surender Kumar, AH Zargar, Sagar Singhal, Raman Shetty, MA Ganie, Sarita Bajaj
November 2013, 17(8):491-495
DOI
:10.4103/2230-8210.122093
PMID
:24404489
Background:
The A
1
chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (
n
= 66,726) in routine clinical care across four continents.
Materials and Methods:
Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from North India.
Results:
A total of 4912 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Patients had started on or were switched to biphasic insulin aspart (
n
= 3619), insulin detemir (
n
= 880), insulin aspart (
n
= 331), basal insulin plus insulin aspart (
n
= 37) and other insulin combinations (
n
= 44). At baseline glycaemic control was poor for both insulin naïve (mean HbA
1
c: 9.8%) and insulin user (mean HbA
1
c: 9.8%) groups. After 24 weeks of treatment, both the study groups showed improvement in HbA
1
c (insulin naïve: −2.7%, insulin users: −2.6%). SADRs including major hypoglycaemic events or episodes did not occur in any of the study patients.
Conclusion:
Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
-
710
192
Feedback
Subscribe
Sitemap
|
What's New
|
Feedback
|
Disclaimer
|
© Indian Journal of Endocrinology and Metabolism | Published by Wolters Kluwer -
Medknow
Online since 10 December, 2010